中关村：公司生物医药板块毛利率符合医药行业整体水平

Core Viewpoint - The company stated that the gross margin of its biopharmaceutical segment aligns with the overall level of the pharmaceutical industry, indicating a commitment to maintaining growth and technological leadership through significant R&D investments, which currently depress overall net profit levels. The company anticipates that once R&D outcomes are converted into products, this will enhance the overall net profit of the biopharmaceutical segment [1]. Group 1 - The biopharmaceutical segment's gross margin is consistent with the pharmaceutical industry's average [1] - The company is investing heavily in R&D to ensure sustained growth and technological advancement [1] - Current R&D expenditures are temporarily lowering the overall net profit levels [1] Group 2 - The company expects that successful R&D outcomes will eventually translate into products, improving net profit levels in the biopharmaceutical segment [1]